Allosteric inhibition of Bcr-Abl kinase by high affinity monobody inhibitors directed to the Src homology 2 (SH2)-kinase interface

Journal of Biological Chemistry

Volumn 291, Issue 16, 2016, Pages 8836-8847

  Wojcik, John ^a   Lamontanara, Allan Joaquim ^b   Grabe, Grzegorz ^a,c   Koide, Akiko ^a   Akin, Louesa ^a   Gerig, Barbara ^b   Hantschel, Oliver ^b   Koide, Shohei ^a,d  

^a UNIVERSITY OF CHICAGO   (United States)

^b EPFL   (Switzerland)

^c UNIVERSITY OF GDA SK   (Poland)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINS; CELL CULTURE; CELL DEATH; DISEASES;

ALLOSTERIC INHIBITION; BINDING PROTEINS; BINDING SURFACE; CHRONIC MYELOGENOUS LEUKEMIA; CONSTITUTIVELY ACTIVES; INTERACTION INTERFACE; KINASE ACTIVITY; PHOSPHOTYROSINE BINDINGS;

ENZYMES;

BCR ABL INHIBITOR; BCR ABL PROTEIN; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN SH2; UNCLASSIFIED DRUG; BCR-ABL1 FUSION PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ALLOSTERISM; APOPTOSIS; ARTICLE; BINDING SITE; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSFECTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; K562 CELL LINE; MUTAGENESIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PURIFICATION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; SRC HOMOLOGY DOMAIN; TUMOR CELL LINE;

ALLOSTERIC REGULATION; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HUMANS; SRC HOMOLOGY DOMAINS;

EID: 84966320531     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M115.707901     Document Type: Article

References (35)

1. Holohan, C., Van Schaeybroeck, S., Longley, D. B., and Johnston, P. G. (2013) Cancer drug resistance: an evolving paradigm. Nat. Rev. Cancer 13, 714-726
2. Shah, N. P., and Sawyers, C. L. (2003) Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22, 7389-7395
3. Deininger, M. W., and Goldman., J. M., and Melo, J. V. (2000) The molecular biology of chronic myeloid leukemia. Blood 96, 3343-3356
4. Shah, N. P., and Nicoll., J. M., Nagar, B., Gorre, M. E., and Paquette., R. L., Kuriyan, J., and Sawyers, C. L. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2, 117-125
5. Hantschel, O., Grebien, F., and Superti-Furga, G. (2012) The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL. Cancer Res. 72, 4890-4895
6. Wylie, A., Schoepfer, J., Berellini, G., Cai, H., Caravatti, G., Cotesta, S., Dodd, S., Donovan, J., Erb, B., Furet, P., Gangal, G., Grotzfeld, R., Hassan, Q., Hood, T., Iyer, V., et al. (2014) ABL001, a potent allosteric inhibitor of BCR-ABL, prevents emergence of resistant disease when administered in combination with nilotinib in an in vivo murine model of chronic myeloid leukemia. Blood 124, 398
7. Hantschel, O., and Superti-Furga, G. (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat. Rev. Mol. Cell Biol. 5, 33-44
8. Filippakopoulos, P., Kofler, M., Hantschel, O., Gish, G. D., Grebien, F., Salah, E., Neudecker, P., Kay, L. E., and Turk., B. E., Superti-Furga, G., Pawson, T., and Knapp, S. (2008) Structural coupling of SH2-kinase domains links Fes and Abl substrate recognition and kinase activation. Cell 134, 793-803
9. Grebien, F., Hantschel, O., Wojcik, J., Kaupe, I., Kovacic, B., Wyrzucki, A. M., and Gish., G. D., Cerny-Reiterer, S., Koide, A., Beug, H., Pawson, T., Valent, P., Koide, S., and Superti-Furga, G. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147, 306-319
10. Koide, A., and Bailey., C. W., Huang, X., and Koide, S. (1998) The fibronectin type III domain as a scaffold for novel binding proteins. J. Mol. Biol. 284, 1141-1151
11. Koide, A., Wojcik, J., Gilbreth, R. N., and Hoey., R. J., and Koide, S. (2012) Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J. Mol. Biol. 415, 393-405
12. Koide, S., Koide, A., and Lipovšek, D. (2012) Target-binding proteins based on the 10th human fibronectin type III domain ((10)Fn3). Methods Enzymol. 503, 135-156
13. Wojcik, J., Hantschel, O., Grebien, F., Kaupe, I., and Bennett., K. L., Barkinge, J., Jones, R.B., Koide, A., Superti-Furga, G., and Koide, S. (2010) A potent and highly specific FN3 monobody inhibitor of the Abl SH2 domain. Nat. Struct. Mol. Biol. 17, 519-527
14. Koide, A., and Gilbreth., R. N., Esaki, K., Tereshko, V., and Koide, S. (2007) High-affinity single-domain binding proteins with a binary-code interface. Proc. Natl. Acad. Sci. U.S.A. 104, 6632-6637
15. Kunkel, T. A., and Roberts., J. D., and Zakour, R. A. (1987) Rapid and efficient site-directed mutagenesis without phenotypic selection. Methods Enzymol. 154, 367-382
16. Lamontanara, A. J., Georgeon, S., Tria, G., Svergun, D. I., and Hantschel, O. (2014) The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility. Nat. Commun. 5, 5470
17. Koide, A., Wojcik, J., Gilbreth, R. N., Reichel, A., Piehler, J., and Koide, S. (2009) Accelerating phage-display library selection by reversible and site specific biotinylation. Protein Eng. Des. Sel. 22, 685-690
18. Otwinowski, Z., and Minor, W. (1997) Processing of x-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307-326
19. Collaborative Computational Project, Number 4 (1994) The CCP4 Suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763
20. Potterton, E., Briggs, P., Turkenburg, M., and Dodson, E. (2003) A graphical user interface to the CCP4 program suite. Acta Crystallogr. D Biol. Crystallogr. 59, 1131-1137
21. Brunger, A.T. (2007) Version 1.2 of the Crystallography and NMR system. Nat. Protoc. 2, 2728-2733
22. Brünger, A. T. (1992) X-PLOR: A System for X-ray Crystallography and NMR, Version 3.1, Yale University Press, New Haven, CT
23. Painter, J., and Merritt, E. A. (2006) Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D Biol. Crystallogr. 62, 439-450
24. Emsley, P., and Cowtan, K. (2004) Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132
25. Reynolds, C., Damerell, D., and Jones, S. (2009) ProtorP: a protein-protein interaction analysis server. Bioinformatics 25, 413-414
26. Lawrence, M. C., and Colman, P. M. (1993) Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950
27. Barilá, D., and Superti-Furga, G. (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat. Genet. 18, 280-282
28. Gilbreth, R. N., and Koide, S. (2012) Structural insights for engineering binding proteins basedonnon-antibody scaffolds. Curr. Opin. Struct. Biol. 22, 413-420
29. Huang, X., Yang, X., Luft, B. J., and Koide, S. (1998) NMR identification of epitopes of Lyme disease antigen OspA to monoclonal antibodies. J. Mol. Biol. 281, 61-67
30. Sha, F., and Gencer., E. B., Georgeon, S., Koide, A., Yasui, N., Koide, S., and Hantschel, O. (2013) Dissection of the BCR-ABL signaling network using highly specific monobody inhibitors to the SHP2 SH2 domains. Proc. Natl. Acad. Sci. U.S.A. 110, 14924-14929
31. Nagar, B., Hantschel, O., Seeliger, M., Davies, J. M., and Weis., W. I., Superti Furga, G., and Kuriyan, J. (2006) Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol. Cell 21, 787-798
32. Sherbenou, D. W., Hantschel, O., Kaupe, I., Willis, S., Bumm, T., Turaga, L. P., Lange, T., Dao, K.H., and Press., R. D., Druker, B.J., Superti-Furga, G., and Deininger, M. W. (2010) BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood 116, 3278-3285
33. Adrián, F. J., Ding, Q., Sim, T., Velentza, A., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P., Mestan, J., Fabbro, D., and Gray, N. S. (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat. Chem. Biol. 2, 95-102
34. Hantschel, O., Gstoettenbauer, A., Colinge, J., Kaupe, I., Bilban, M., Burkard, T. R., Valent, P., and Superti-Furga, G. (2008) The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia. Mol. Oncol. 2, 272-281
35. Erlanson, D. A., and Wells., J. A., and Braisted, A. C. (2004) Tethering: fragment-based drug discovery. Annu. Rev. Biophys. Biomol. Struct. 33, 199-223